Trevena, Inc. (NASDAQ:TRVN) today announced that it will be attending the following investor conferences in June:
The Jefferies and Marcum presentations will be webcast live. To join, please visit the Investor section of the Company’s website. Following the conclusion of each presentation, the webcast will be available for replay for 30 days.
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO™ (oliceridine injection), currently in Phase 3 development for the management of moderate-to-severe acute pain. Trevena also has discovered TRV250, in early clinical development for the treatment of migraine, and TRV734, for pain. The Company is actively working on an early stage portfolio of drug discovery programs.
Jonathan Violin, Ph.D.
Vice President, Corporate Strategy & Investor Relations
Copyright © Trevena, Inc.